AnaptysBio (NASDAQ:ANAB) Insider Sells $510,000.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $51.00, for a total transaction of $510,000.00. Following the completion of the transaction, the insider directly owned 8,947 shares of the company’s stock, valued at $456,297. This trade represents a 52.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

AnaptysBio Trading Down 0.0%

Shares of NASDAQ ANAB opened at $50.03 on Friday. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $51.43. The stock’s fifty day simple moving average is $40.14 and its two-hundred day simple moving average is $29.69. The stock has a market capitalization of $1.39 billion, a PE ratio of -17.74 and a beta of 0.29.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The firm had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. On average, equities analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has approved a stock buyback plan on Friday, November 21st that permits the company to buyback $100.00 million in shares. This buyback authorization permits the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the stock. Larson Financial Group LLC increased its position in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the period. Bessemer Group Inc. grew its stake in AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares during the period. Osaic Holdings Inc. increased its holdings in shares of AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares during the period. Finally, Profund Advisors LLC purchased a new position in shares of AnaptysBio in the third quarter worth about $201,000.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. Truist Financial upped their price target on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. Wedbush reiterated an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a report on Monday, November 24th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Finally, HC Wainwright dropped their target price on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $55.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.